5 results about "Hypoxic tumor" patented technology

The application discloses a kind of lipid droplet targeted NIR-I photothermal agent and its application in hypoxic tumor treatment, belong to the technical field of photothermal therapy.The NIR-I photothermal agent of the application is a kind of organic photothermal material based on donor-acceptor structure, with strong electron-deficient and rigid planar structure dithiophene pyrrolone sub benzodifuran diketone (BTPDBDF) as acceptor unit, respectively with triphenylamine and tetraphenyl ethylene as donor unit, with strong intramolecular charge transfer, absorption spectrum reaches near infrared region one.Simultaneously, the material is prepared into water-soluble nanoparticles by nano precipitation method, and the biocompatibility and targeting are improved.The nano preparation has the ability of specific targeting cell lipid droplet, and shows significant heating performance and high photothermal conversion efficiency under 808 nm laser irradiation, and shows good near-infrared light capturing capacity, so as to facilitate effective photothermal therapy under the condition of tumor hypoxia.

This invention belongs to the field of pharmaceutical chemistry technology, specifically relating to a near-infrared II luminescent iridium(III) complex photosensitizer, its preparation method, and its application. The near-infrared II luminescent iridium(III) complex photosensitizer disclosed in this invention generates singlet oxygen (…) under 550 nm illumination. 1 O2), hydroxyl radicals (•OH), superoxide anions (O2) •‑ We evaluated the antitumor activity of near-infrared luminescent iridium complexes using mouse breast cancer cells (4T1). Under unilluminated conditions, the near-infrared II luminescent iridium(III) complex photosensitizers showed no significant cytotoxicity to 4T1 cells, while under illumination, they exhibited good phototoxicity to 4T1 cells, with an IC50 value of [missing value]. 50 The concentration is 15.92 μM. We have invented a near-infrared II luminescent iridium(III) complex photosensitizer, which has excellent photoimmunodynamic therapeutic effects and will have important application prospects in the treatment of hypoxic tumors.

This invention relates to the field of cell culture technology, and discloses a method for culturing NK cells and its applications. When NK cells enter a hypoxic environment, not only do their cytotoxic activity and proliferative capacity rapidly decline, but they also experience metabolic disorders such as impaired mitochondrial function, insufficient ATP production, and abnormal accumulation of reactive oxygen species (ROS), leading to functional failure and limiting their application in tumor therapy. Existing technologies mainly rely on constant or single-stage hypoxia induction, failing to improve the insufficient hypoxia adaptation of NK cells at the metabolic level. Therefore, this invention provides a method that uses repeated acclimatization culture with gradually decreasing oxygen concentration to allow NK cells to gradually adapt to the metabolic demands of a hypoxic environment. NK cells cultured using this method exhibit a more stable metabolic state and superior cytotoxic activity in a hypoxic environment, significantly enhancing their anti-tumor efficacy and solving the problem of metabolic imbalance and rapid functional loss of NK cells in the hypoxic tumor microenvironment in existing technologies.

This invention discloses a tumor cell hypoxia-sensitive fluorescent probe, its preparation method, and its application, belonging to the field of biomedical application technology. The tumor cell hypoxia-sensitive fluorescent probe provided by this invention uses triazine as the response unit, responding to the cellular microenvironment and being sensitive to hypoxia. It exhibits a significant specific activation effect in hypoxic tumor cells, enabling precise and efficient identification of hypoxic tumor cells.

This invention discloses a nano-heterojunction radiosensitizer suitable for hypoxic tumors and its preparation method. The radiosensitizer is a core-shell structured nanoparticle, comprising a core and a shell. The core is a high-valence bismuth-based nanomaterial, including at least one of sodium bismuthate, silver bismuthate, and potassium bismuthate. The shell coats the surface of the core and comprises a metal oxide. A Z-shaped heterojunction is formed between the inner core and the outer shell. Under X-ray excitation, this heterojunction forms a built-in electric field, promoting electron-hole separation. Electrons in the high-valence bismuth nanoparticle phase reduce high-valence bismuth (Bi). 5+ →Bi 3+ ) and releases highly reactive lattice oxygen, which then reacts with holes on the TiO2 phase to generate singlet oxygen ( 1 O2), while the holes on TiO2 oxidize water molecules to produce hydroxyl radicals (•OH).